Sorrento Publishes an Abivertinib Teaser Entitled “Abivertinib – A Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune Diseases”
November 29 2021 - 9:00AM
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today
announced the publication of a Teaser titled “Abivertinib – a
Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune
Diseases” (“Abivertinib Teaser”). Sorrento intends to use the
Abivertinib Teaser to engage in discussions with interested third
parties in the pharmaceutical industry.
The key highlights of the Abivertinib Teaser are outlined
below:
- Abivertinib for
COVID-19 (Two Phase 2 trials Completed)
- 100 mg once-a-day
oral capsule for hospitalized COVID-19 patients
- US trial (N=96)
and Brazil trial (N=400)
For Severe Ordinal Scale (OS) Category 5
COVID-19 Patients (“At-Risk Group”) identified to be beneficial
with Abivertinib treatment at Day 28 (D28):
- Abivertinib reduced the risk of death or respiratory failure:
-
by 48% in US trial (death or respiratory failure: 21.7% in the
Abivertinib group vs. 41.7% in the placebo plus Standard of Care
(SoC) control group)
- by 45% in Brazil
trial (death or respiratory failure: 30.4% Abivertinib vs. 55.6%
placebo plus SoC controls)
- Abivertinib
reduced the ICU stay:
- by 2 days in the
US trial (8.6 days average stay in ICU in Abivertinib group vs.
10.6 days in placebo plus SoC control group)
- Abivertinib for
Cancer IndicationsNSCLC (Pivotal Trial: N=229) - Among 209 response
evaluable NSCLC patients who developed resistance to first line
Tyrosine Kinase Inhibitors (TKIs):
- 93.3% (n/N: 195/209) subjects
achieved tumor shrinkage at target lesions
- 57.4% (n/N: 120/209) subjects achieved the best ORR (confirmed
+ unconfirmed PR)
- 52.2% (n/N: 109/209) subjects achieved confirmed PR
- 24.9 months OS A photo accompanying
this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/e4eef482-cf01-4671-8e82-58fb8a474f3c
B-Cell Lymphoma (Phase 1/2
Trial) (as of 08/28/2020)
- 63.6% ORR (n/N: 14/22)
- 95.5% DCR (n/N: 21/22)
- 19.7 Months PFS
- Abivertinib – A
Broad Pipeline for Cancer, COVID-19 and Autoimmune Diseases ($61B
Market)
About Sorrento Therapeutics, Inc.
Sorrento is a clinical and commercial stage
biopharmaceutical company developing new therapies to treat cancer,
pain (non-opioid treatments), autoimmune disease and COVID-19.
Sorrento's multimodal, multipronged approach to fighting cancer is
made possible by its extensive immuno-oncology platforms, including
key assets such as fully human antibodies (“G-MAB™ library”),
immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates
(“ADCs”), and oncolytic virus (“Seprehvec™”). Sorrento is also
developing potential antiviral therapies and vaccines against
coronaviruses, including Abivertinib, COVIGUARD™, COVI-AMG™,
COVISHIELD™, COVI-MSC™ and COVIDROPS™; and diagnostic test
solutions, including COVITRACK™, COVISTIX™ and COVITRACE™.
Sorrento's commitment to life-enhancing
therapies for patients is also demonstrated by our effort to
advance a first-in-class (TRPV1 agonist) non-opioid pain management
small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg,
dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel,
viscous gel formulation of a widely used corticosteroid for
epidural injections to treat lumbosacral radicular pain, or
sciatica, and to commercialize ZTlido® (lidocaine topical system)
1.8% for the treatment of post-herpetic neuralgia. RTX has
completed a Phase IB trial for intractable pain associated with
cancer and a Phase 1B trial in osteoarthritis patients. SEMDEXA is
in a pivotal Phase 3 trial for the treatment of lumbosacral
radicular pain, or sciatica. ZTlido® was approved by the FDA on
February 28, 2018.
For more information visit
www.sorrentotherapeutics.com.
Forward-Looking Statements
This press release and any statements made for
and during any presentation or meeting contain forward-looking
statements related to Sorrento Therapeutics, Inc., under the safe
harbor provisions of Section 21E of the Private Securities
Litigation Reform Act of 1995 and subject to risks and
uncertainties that could cause actual results to differ materially
from those projected. Forward-looking statements include statements
regarding abivertinib, including the potential safety and clinical
benefits thereof; the efficacy of abivertinib in COVID-19 patients,
non-small cell lung cancer patients and B-Cell lymphoma patients;
the potential for data results to be replicated or continue to show
improved clinical safety or efficacy; and Sorrento’s position in
the pharmaceutical industry. Risks and uncertainties that could
cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements, include, but are
not limited to: risks related to Sorrento's technologies and
prospects, including, but not limited to risks related to seeking
regulatory approval for abivertinib; clinical development risks,
including risks in the progress, timing, cost, and results of
clinical trials and product development programs; risk of
difficulties or delays in obtaining regulatory approvals; risks
that clinical study results may not meet any or all endpoints of a
clinical study and that any data generated from such studies may
not support a regulatory submission or approval; risks that prior
test, study and trial results may not be replicated in future
studies and trials; risks of manufacturing and supplying drug
product; risks related to leveraging the expertise of its
employees, subsidiaries, affiliates and partners to assist Sorrento
in the execution of its therapeutic antibody product candidate
strategies; risks related to the global impact of COVID-19; and
other risks that are described in Sorrento's most recent periodic
reports filed with the Securities and Exchange Commission,
including Sorrento's Annual Report on Form 10-K for the year ended
December 31, 2020, and subsequent Quarterly Reports on Form 10-Q
filed with the Securities and Exchange Commission, including the
risk factors set forth in those filings. Investors are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date of this release and we undertake no
obligation to update any forward-looking statement in this press
release except as required by law.
Media and Investor Relations
ContactDorman FollowwillEmail:
mediarelations@sorrentotherapeutics.com
Sorrento® and the Sorrento logo are registered
trademarks of Sorrento Therapeutics, Inc.
G-MAB™, DAR-T™, SOFUSA™, COVIGUARD™, COVI-AMG™,
COVISHIELD™, COVIDROPS™, COVI-MSC™, COVITRACK™, COVITRACE™ and
COVISTIX™ are trademarks of Sorrento Therapeutics, Inc.
SEMDEXA™ is a trademark of Semnur
Pharmaceuticals, Inc.
ZTlido® is a registered trademark owned by
Scilex Pharmaceuticals Inc.
All other trademarks are the property of their
respective owners.
©2021 Sorrento Therapeutics, Inc. All Rights
Reserved.
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Sep 2023 to Sep 2024